Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Legendre CM, et al. Among authors: greenbaum la. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. N Engl J Med. 2013. PMID: 23738544 Free article. Clinical Trial.
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Licht C, et al. Among authors: greenbaum la. Kidney Int. 2015 May;87(5):1061-73. doi: 10.1038/ki.2014.423. Epub 2015 Feb 4. Kidney Int. 2015. PMID: 25651368 Free PMC article. Clinical Trial.
The global aHUS registry: methodology and initial patient characteristics.
Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V. Licht C, et al. Among authors: greenbaum la. BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1. BMC Nephrol. 2015. PMID: 26654630 Free PMC article.
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V; Global aHUS Registry. Schaefer F, et al. Among authors: greenbaum la. Kidney Int. 2018 Aug;94(2):408-418. doi: 10.1016/j.kint.2018.02.029. Epub 2018 Jun 19. Kidney Int. 2018. PMID: 29907460 Free article.
Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study.
Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Menne J, et al. Among authors: greenbaum la. Clin Kidney J. 2018 May 16;12(2):196-205. doi: 10.1093/ckj/sfy035. eCollection 2019 Apr. Clin Kidney J. 2018. PMID: 30976396 Free PMC article.
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. Ariceta G, et al. Among authors: greenbaum la. Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8. Kidney Int. 2021. PMID: 33307104 Free article. Clinical Trial.
201 results